500 related articles for article (PubMed ID: 15695169)
21. Melatonin-enhanced hyperactivation of hamster sperm.
Fujinoki M
Reproduction; 2008 Nov; 136(5):533-41. PubMed ID: 18715981
[TBL] [Abstract][Full Text] [Related]
22. Fresh from the pipeline: Ramelteon.
Buysse D; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
[No Abstract] [Full Text] [Related]
23. 17Beta-estradiol modulates hMT1 melatonin receptor function.
Masana MI; Soares JM; Dubocovich ML
Neuroendocrinology; 2005; 81(2):87-95. PubMed ID: 15809517
[TBL] [Abstract][Full Text] [Related]
24. The role of proline residues in the structure and function of human MT2 melatonin receptor.
Mazna P; Grycova L; Balik A; Zemkova H; Friedlova E; Obsilova V; Obsil T; Teisinger J
J Pineal Res; 2008 Nov; 45(4):361-72. PubMed ID: 18544139
[TBL] [Abstract][Full Text] [Related]
25. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
Karim A; Tolbert D; Cao C
J Clin Pharmacol; 2006 Feb; 46(2):140-8. PubMed ID: 16432265
[TBL] [Abstract][Full Text] [Related]
26. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation.
Kokkola T; Vaittinen M; Laitinen JT
J Pineal Res; 2007 Oct; 43(3):255-62. PubMed ID: 17803522
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in melatonin receptor ligands.
Zlotos DP
Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
[TBL] [Abstract][Full Text] [Related]
28. In vitro comparison of duration of action of melatonin agonists on melatonin MT1 receptor: possible link between duration of action and dissociation rate from receptor.
Nishiyama K; Hirai K
Eur J Pharmacol; 2015 Jun; 757():42-52. PubMed ID: 25797281
[TBL] [Abstract][Full Text] [Related]
29. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
Arai M
Headache; 2015; 55(7):1010-1. PubMed ID: 26121162
[No Abstract] [Full Text] [Related]
30. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
[TBL] [Abstract][Full Text] [Related]
31. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
32. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
[TBL] [Abstract][Full Text] [Related]
33. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
[TBL] [Abstract][Full Text] [Related]
34. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.
Greenblatt DJ; Harmatz JS; Karim A
J Clin Pharmacol; 2007 Apr; 47(4):485-96. PubMed ID: 17389558
[TBL] [Abstract][Full Text] [Related]
35. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
Ayoub MA; Levoye A; Delagrange P; Jockers R
Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
[TBL] [Abstract][Full Text] [Related]
36. Structural basis of the ligand binding and signaling mechanism of melatonin receptors.
Wang Q; Lu Q; Guo Q; Teng M; Gong Q; Li X; Du Y; Liu Z; Tao Y
Nat Commun; 2022 Jan; 13(1):454. PubMed ID: 35075127
[TBL] [Abstract][Full Text] [Related]
37. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
[TBL] [Abstract][Full Text] [Related]
38. Ramelteon: profile of a new sleep-promoting medication.
Owen RT
Drugs Today (Barc); 2006 Apr; 42(4):255-63. PubMed ID: 16703122
[TBL] [Abstract][Full Text] [Related]
39. New ligands at the melatonin binding site MT(3).
Boussard MF; Truche S; Rousseau-Rojas A; Briss S; Descamps S; Droual M; Wierzbicki M; Ferry G; Audinot V; Delagrange P; Boutin JA
Eur J Med Chem; 2006 Mar; 41(3):306-20. PubMed ID: 16414149
[TBL] [Abstract][Full Text] [Related]
40. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
